SCHEMBL7875409

SCHEMBL7875409

CCOC(=O)c1cnc2cccc(C)n12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.51
IDO1 P14902 5/20 0.51
KDM4E B2RXH2 3/20 0.47
CYP1A2 P05177 3/20 0.45
TGFBR1 P36897 1/20 0.45
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
GLA P06280 2/20 0.42
MAPK1 P28482 1/20 0.42
CYP3A4 P08684 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
LMNA P02545 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8587743 0.88 GAA (0.48) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL7872427 0.86 IDO1 (0.46) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL8607204 0.86 IDO1 (0.50) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL8607422 0.85 IDO1 (0.45) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL7863563 0.83 IDO1 (0.46) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL8607489 0.83 IDO1 (0.46) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL11248747 0.82 KDM4E (0.60) GAAKDM4ECYP1A2GLAMAPK1
SCHEMBL8607817 0.81 IDO1 (0.43) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL7875517 0.80 GAA (0.43) GAAIDO1KDM4ECYP1A2TGFBR1
SCHEMBL12549923 0.80 IDO1 (0.44) GAAIDO1KDM4ECYP1A2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9249666-A None JP disclosed
US-20010051631-A1 Tricyclic compounds, their production and use TAKATANI MUNEO (JP) 2001-12-13 US disclosed
US-6251905-B1 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
US-5958942-A HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-09-28 US disclosed
WO-1998029136-A1 STABILIZED TRICYCLIC COMPOUND TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-07-09 WO disclosed
EP-0826686-A2 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-04 EP disclosed
JP-H09249666-A PRODUCTION OF TRICYCLIC COMPOUND AND ITS INTERMEDIATE TAKEDA CHEM IND LTD 1997-09-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051631-A1 Tricyclic compounds, their production and use PDGFA, HGF, REN GAA 3830/4885IDO1 795/4885KDM4E 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.